332 related articles for article (PubMed ID: 12023525)
21. The anti-inflammatory activities of cannabinoid receptor ligands in mouse peritonitis models.
Smith SR; Denhardt G; Terminelli C
Eur J Pharmacol; 2001 Nov; 432(1):107-19. PubMed ID: 11734194
[TBL] [Abstract][Full Text] [Related]
22. Modulation of gastric emptying and gastrointestinal transit in rats through intestinal cannabinoid CB(1) receptors.
Landi M; Croci T; Rinaldi-Carmona M; Maffrand JP; Le Fur G; Manara L
Eur J Pharmacol; 2002 Aug; 450(1):77-83. PubMed ID: 12176112
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of improgan antinociception by the cannabinoid (CB)(1) antagonist N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A): lack of obligatory role for endocannabinoids acting at CB(1) receptors.
Hough LB; Nalwalk JW; Stadel R; Timmerman H; Leurs R; Paria BC; Wang X; Dey SK
J Pharmacol Exp Ther; 2002 Oct; 303(1):314-22. PubMed ID: 12235266
[TBL] [Abstract][Full Text] [Related]
24. Cannabinoid receptor-mediated apoptosis induced by R(+)-methanandamide and Win55,212-2 is associated with ceramide accumulation and p38 activation in mantle cell lymphoma.
Gustafsson K; Christensson B; Sander B; Flygare J
Mol Pharmacol; 2006 Nov; 70(5):1612-20. PubMed ID: 16936228
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of the cannabinoid CB2 receptor-selective antagonist, SR144528: further evidence for cannabinoid CB2 receptor absence in the rat central nervous system.
Griffin G; Wray EJ; Tao Q; McAllister SD; Rorrer WK; Aung MM; Martin BR; Abood ME
Eur J Pharmacol; 1999 Jul; 377(1):117-25. PubMed ID: 10448934
[TBL] [Abstract][Full Text] [Related]
26. Anandamide-mediated CB1/CB2 cannabinoid receptor--independent nitric oxide production in rabbit aortic endothelial cells.
McCollum L; Howlett AC; Mukhopadhyay S
J Pharmacol Exp Ther; 2007 Jun; 321(3):930-7. PubMed ID: 17379772
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of interleukin-8 release in the human colonic epithelial cell line HT-29 by cannabinoids.
Ihenetu K; Molleman A; Parsons ME; Whelan CJ
Eur J Pharmacol; 2003 Jan; 458(1-2):207-15. PubMed ID: 12498928
[TBL] [Abstract][Full Text] [Related]
28. R+-methanandamide inhibits tracheal response to endogenously released acetylcholine via capsazepine-sensitive receptors.
Nieri P; Martinotti E; Testai L; Adinolfi B; Calderone V; Breschi MC
Eur J Pharmacol; 2003 Jan; 459(1):75-81. PubMed ID: 12505536
[TBL] [Abstract][Full Text] [Related]
29. Effects of pharmacological manipulations of cannabinoid receptors on severity of dystonia in a genetic model of paroxysmal dyskinesia.
Richter A; Löscher W
Eur J Pharmacol; 2002 Nov; 454(2-3):145-51. PubMed ID: 12421641
[TBL] [Abstract][Full Text] [Related]
30. Characterization of cannabinoid modulation of sensory neurotransmission in the rat isolated mesenteric arterial bed.
Duncan M; Kendall DA; Ralevic V
J Pharmacol Exp Ther; 2004 Oct; 311(1):411-9. PubMed ID: 15205450
[TBL] [Abstract][Full Text] [Related]
31. The cannabinoid receptor agonist WIN 55212-2 inhibits neurogenic inflammations in airway tissues.
Yoshihara S; Morimoto H; Ohori M; Yamada Y; Abe T; Arisaka O
J Pharmacol Sci; 2005 May; 98(1):77-82. PubMed ID: 15888960
[TBL] [Abstract][Full Text] [Related]
32. Systemic effect of cannabinoids on the spontaneous firing rate of locus coeruleus neurons in rats.
Mendiguren A; Pineda J
Eur J Pharmacol; 2006 Mar; 534(1-3):83-8. PubMed ID: 16483566
[TBL] [Abstract][Full Text] [Related]
33. Intravenous self-administration of the cannabinoid CB1 receptor agonist WIN 55,212-2 in rats.
Fattore L; Cossu G; Martellotta CM; Fratta W
Psychopharmacology (Berl); 2001 Aug; 156(4):410-6. PubMed ID: 11498718
[TBL] [Abstract][Full Text] [Related]
34. The cannabinoid CB1 receptor antagonist SR 141716A reverses the antiemetic and motor depressant actions of WIN 55, 212-2.
Darmani NA
Eur J Pharmacol; 2001 Oct; 430(1):49-58. PubMed ID: 11698062
[TBL] [Abstract][Full Text] [Related]
35. Milk intake and survival in newborn cannabinoid CB1 receptor knockout mice: evidence for a "CB3" receptor.
Fride E; Foox A; Rosenberg E; Faigenboim M; Cohen V; Barda L; Blau H; Mechoulam R
Eur J Pharmacol; 2003 Feb; 461(1):27-34. PubMed ID: 12568912
[TBL] [Abstract][Full Text] [Related]
36. Regulation of inflammatory pain by inhibition of fatty acid amide hydrolase.
Naidu PS; Kinsey SG; Guo TL; Cravatt BF; Lichtman AH
J Pharmacol Exp Ther; 2010 Jul; 334(1):182-90. PubMed ID: 20375198
[TBL] [Abstract][Full Text] [Related]
37. Antitussive effect of WIN 55212-2, a cannabinoid receptor agonist.
Morita K; Kamei J
Eur J Pharmacol; 2003 Aug; 474(2-3):269-72. PubMed ID: 12921873
[TBL] [Abstract][Full Text] [Related]
38. Inhibitory effect of cannabinoid agonists on gastric emptying in the rat.
Izzo AA; Mascolo N; Capasso R; Germanò MP; De Pasquale R; Capasso F
Naunyn Schmiedebergs Arch Pharmacol; 1999 Aug; 360(2):221-3. PubMed ID: 10494894
[TBL] [Abstract][Full Text] [Related]
39. Inhibitory effect of the cannabinoid receptor agonist WIN 55,212-2 on pentagastrin-induced gastric acid secretion in the anaesthetized rat.
Coruzzi G; Adami M; Coppelli G; Frati P; Soldani G
Naunyn Schmiedebergs Arch Pharmacol; 1999 Dec; 360(6):715-8. PubMed ID: 10619190
[TBL] [Abstract][Full Text] [Related]
40. Effect of chronic administration of R-(+)-[2,3-Dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate (WIN55,212-2) or delta(9)-tetrahydrocannabinol on cannabinoid receptor adaptation in mice.
Sim-Selley LJ; Martin BR
J Pharmacol Exp Ther; 2002 Oct; 303(1):36-44. PubMed ID: 12235230
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
